UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The "rights" of precision drug development for Alzheimer's disease

Alzheimer's research & therapy, 2019-08, Vol.11 (1), p.76-14, Article 76

2019

Volltextzugriff (PDF)

Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy

Dementia and geriatric cognitive disorders, 2010-01, Vol.30 (2), p.161-178

2010

Volltextzugriff (PDF)

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease

Frontiers in pharmacology, 2023-08, Vol.14, p.1190402-1190402

2023

Volltextzugriff (PDF)

The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study

Canadian journal of neurological sciences, 2019-09, Vol.46 (5), p.499-511

2019

Volltextzugriff (PDF)

Diagnosis and treatment of dementia: 2. Diagnosis

Canadian Medical Association journal, 2008-03, Vol.178 (7), p.825-836

2008

Volltextzugriff (PDF)

Multidomain trials to prevent dementia: addressing methodological challenges

Alzheimer's research & therapy, 2022-07, Vol.14 (1), p.1-94, Article 94

2022

Volltextzugriff (PDF)

Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)

Alzheimer's research & therapy, 2018-09, Vol.10 (1), p.102-102, Article 102

2018

Volltextzugriff (PDF)

Potential for misclassification of mild cognitive impairment: A study of memory scores on the Wechsler Memory Scale-III in healthy older adults

Journal of the International Neuropsychological Society, 2008-05, Vol.14 (3), p.463-478

2008

Volltextzugriff (PDF)

Ubiquitin Immunohistochemistry Suggests Classic Motor Neuron Disease, Motor Neuron Disease With Dementia, and Frontotemporal Dementia of the Motor Neuron Disease Type Represent a Clinicopathologic Spectrum

Journal of neuropathology and experimental neurology, 2005-08, Vol.64 (8), p.730-739

2005

Volltextzugriff (PDF)

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease

Alzheimer's research & therapy, 2024-07, Vol.16 (1), p.151-15, Article 151

2024

Volltextzugriff (PDF)

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

Depression and anxiety, 2010-05, Vol.27 (5), p.417-425

2010

Volltextzugriff (PDF)

Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency

Molecular neurodegeneration, 2020-03, Vol.15 (1), p.21-19, Article 21

2020

Volltextzugriff (PDF)

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia

Alzheimer's & dementia : translational research & clinical interventions, 2021, Vol.7 (1), p.e12106-n/a

2021

Volltextzugriff (PDF)

Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective

Alzheimer's & dementia : translational research & clinical interventions, 2024-04, Vol.10 (2), p.e12463-n/a

2024

Volltextzugriff (PDF)

Developing the Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program

Alzheimer's & dementia : translational research & clinical interventions, 2024-01, Vol.10 (1), p.e12457-n/a

2024

Volltextzugriff (PDF)

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients

Alzheimer's & dementia : translational research & clinical interventions, 2024-07, Vol.10 (3), p.e12490-n/a

2024

Volltextzugriff (PDF)

Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease

Frontiers in medicine, 2022-10, Vol.9, p.1033272-1033272

2022

Volltextzugriff (PDF)

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Neurology, 2016-08, Vol.87 (5), p.539-547

2016

Volltextzugriff (PDF)

CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease

Nature reviews. Neurology, 2022-07, Vol.18 (7), p.379-380

2022

Volltextzugriff (PDF)

Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers

NeuroImage clinical, 2018-01, Vol.18, p.591-598

2018

Volltextzugriff (PDF)

Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study

Alzheimer's research & therapy, 2021-12, Vol.13 (1), p.201-201, Article 201

2021

Volltextzugriff (PDF)

Clinical value of Alzheimer's disease biomarker testing

Alzheimer's & dementia : translational research & clinical interventions, 2024-04, Vol.10 (2), p.e12464-n/a

2024

Volltextzugriff (PDF)

Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures

Alzheimer's & dementia : translational research & clinical interventions, 2020, Vol.6 (1), p.e12071-n/a

2020

Volltextzugriff (PDF)

Home EEG sleep assessment shows reduced slow‐wave sleep in mild–moderate Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2022, Vol.8 (1), p.e12347-n/a

2022

Volltextzugriff (PDF)

1 – 25 von 412

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(368)
Mit Volltextzugriff
(267)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(411)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

The "rights" of precision drug development for Alzheimer's disease

Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease

The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study

Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam)

Diagnosis and treatment of dementia: 2. Diagnosis

Multidomain trials to prevent dementia: addressing methodological challenges

Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)

Potential for misclassification of mild cognitive impairment: A study of memory scores on the Wechsler Memory Scale-III in healthy older adults

Ubiquitin Immunohistochemistry Suggests Classic Motor Neuron Disease, Motor Neuron Disease With Dementia, and Frontotemporal Dementia of the Motor Neuron Disease Type Represent a Clinicopathologic Spectrum

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia

Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective

Developing the Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients

Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease

Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers

Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study

Clinical value of Alzheimer's disease biomarker testing

Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures

Home EEG sleep assessment shows reduced slow‐wave sleep in mild–moderate Alzheimer's disease

Aktive Filter

Suchergebnisse filtern